Education
About Us
Working with TipRanks
Follow Us
Genomtec SA (DE:4VI)
FRANKFURT:4VI
4VI Stock Chart & Stats
Day’s Range― - ―
52-Week Range€1.38 - €2.50
Previous CloseN/A
Volume0.00
Average Volume (3M)149.00
Market Cap
€25.27M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta>-0.01
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding14,867,126
10 Day Avg. Volume0
30 Day Avg. Volume149
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
4VI FAQ
What was Genomtec SA’s price range in the past 12 months?
Genomtec SA lowest stock price was €1.38 and its highest was €2.50 in the past 12 months.
What is Genomtec SA’s market cap?
Genomtec SA’s market cap is €25.27M.
When is Genomtec SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Genomtec SA’s earnings last quarter?
Currently, no data Available
Is Genomtec SA overvalued?
According to Wall Street analysts Genomtec SA’s price is currently Overvalued.
Does Genomtec SA pay dividends?
Genomtec SA does not currently pay dividends.
What is Genomtec SA’s EPS estimate?
Genomtec SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genomtec SA have?
Genomtec SA has 14,867,126 shares outstanding.
What happened to Genomtec SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Genomtec SA?
Currently, no hedge funds are holding shares in DE:4VI
Company Description
Genomtec SA
Genomtec S.A. researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. The company develops Genomtec ID, a technological device that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analyzing the biological material of patients using swabs, urine samples, saliva, blood, and other body fluids. It also develops Genomtec Tumor, a SNAAT based solution used to identify neoplastic mutations and mutations with prognostic value in neoplastic disease; Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit to detect SARS-CoV-2 RNA in various biological samples from patients with suspected COVID-19 infection; and Genomtec RT-LAMP CE-IVD Duo-Kit for the detection of all variants of the SARS-CoV-2 virus. Genomtec S.A was founded in 2016 and is based in Wroclaw, Poland.